Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the availability of propranolol in pharmacies; and what steps he is taking to ensure supply.

The Department is aware of supply issues affecting propranolol 80 milligram and 160 milligram modified release (MR) capsules due to ongoing manufacturing issues which are expected to last until at least July 2026.

The Department is working with all suppliers to help resolve the issues and improve supplies, including asking that they source stock from other markets. We have also reached out to specialist importers who have sourced unlicensed imports of propranolol 80 milligram and 160 milligram MR capsules. We have engaged with National Health Service specialist clinicians and issued comprehensive guidance on how to manage patients during this time and to advise on available alternative preparations.

The Department continues to work with the supply chain teams and the Medicines and Healthcare products Regulatory Agency to mitigate the situation and ensure supplies are available for patients as soon as possible.